News

Onco360 named to Inc. 5000 list

BY Jason Owen

NEW YORK — Inc. magazine released its annual Inc. 5000 list of top companies and for the second straight year, Onco360 has been named one of the fastest growing companies in America, the company stated. When evaluated by revenue, Onco360 is the No. 1 New York State healthcare company on the list.

Onco360 specializes in oncology pharmacy and the growth the company has been experiencing is proof that its unique approach is resonating with stakeholders, including cancer patients, community and hospital-based oncologists, payers, manufacturers and NCCN Centers of Excellence, the company stated.

“Cancer is very complex to treat, let alone treat effectively, and that’s why Onco360 built itself to service the complex needs of each stakeholder involved in the continuum of cancer care,” said Burt Zweigenhaft, CEO of Onco360.

In addition to being one of the top healthcare companies in New York State, Onco360 obtained other notable rankings, including:

  • One of the Top 25 Healthcare Companies Overall by Revenue;
  • One of the Top 25 New York State Companies Overall by Revenue.

Amvrosios Ioannidis, chief brand and marketing officer of Onco360 added, “As an organization, we’re extremely proud of the work we do helping support cancer patients, and we believe in the company’s potential and promise. To see that validated and recognized by a great organization like Inc., speaks volumes of the important work Onco360 employees do every day.”


Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Elizabeth Arden CFO resigns to accept position at the Hain Celestial Group

BY Antoinette Alexander

NEW YORK — Elizabeth Arden, whose portfolio includes such celebrity fragrance brands as Britney Spears, Elizabeth Taylor and Justin Bieber, has announced the resignation of its EVP and CFO Stephen Smith, effective Sept. 1. Smith is leaving the company to serve as EVP and CFO of the Hain Celestial Group.

Elizabeth Arden is now searching for a new CFO.

 “Steve has been a valuable member of our management team since he joined us in 2001, shortly after the Elizabeth Arden acquisition. Along with the strong finance and accounting team that Steve has built, he has been instrumental in managing the financial governance of our company to very high standards. Steve has been a trusted colleague, and on behalf of the company, I’d like to thank Steve for his dedication, leadership and contributions and wish him the best in his new position,” stated E. Scott Beattie, chairman, president and CEO of Elizabeth Arden.

“The past 12 years have been extremely rewarding, and it has been an honor to participate in the Company’s significant growth over that time,” Smith stated. “While I will miss my colleagues, I look forward to new challenges in another consumer products industry as I pursue this unexpected opportunity. Elizabeth Arden has a strong and highly talented finance organization, and I am confident that Elizabeth Arden will continue to enjoy much future success."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Astellas Pharma introduces Astagraf XL for kidney-transplant patients

BY Alaric DeArment

NORTHBROOK, Ill. — Astellas Pharma has introduced a new drug for preventing the body from rejecting transplanted organs, the company said Thursday.

The drug maker announced the availability of Astagraf XL (tacrolimus) extended-release capsules in pharmacies. The drug is designed for use in kidney transplant patients with Genenetech’s CellCept (mycophenolate mofetil) and corticosteroids, with or without induction of Novartis’ Simulect (basiliximab).

"The availability of Astagraf XL marks a significant moment for the transplantation community, giving new adult kidney transplant recipients an additional option in their immunosuppressant care," Astellas Pharma US president James Robinson said. "Astellas has long been a leader in the field of transplant immunology, and we are proud to continue to advance care for transplant recipients."


Are you a nurse practitioner or physician’s assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?